Paper Details
- Home
- Paper Details
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Author: CanaleFilippo Antonio, ConsoleGiuseppe, CusumanoGiuseppa, Di CostanzoAntonella, FerreriAnna, GalloSalvatore, GangemiTiziana, IrreraGiuseppe, LoddoViviana, LotetaBarbara, MartinoMassimo, MeliambroNicola, MoscatoTiziana, NasoVirginia, PaviglianitiAnnalisa, PorcinoDomenico, PortoGaetana, ProvenzanoPasquale Fabio, PuglieseMarta, RomeoValentina, RossettiAntonio Maria, RussoLetteria
Original Abstract of the Article :
Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent adverse events compromising quality of life (QoL) in patients undergoing autologous stem cell transplantation (ASCT). However, CINV prophylaxis is still lacking uniformity for high-dose melphalan (HDM), which is used to cond...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331991/
データ提供：米国国立医学図書館（NLM）
Netupitant/Palonosetron: A New Antiemetic Option for Multiple Myeloma
The field of [multiple myeloma (MM)] treatment is constantly evolving, seeking to improve patient outcomes and reduce side effects. This study investigates the efficacy of a new antiemetic combination, [netupitant/palonosetron], for preventing [chemotherapy-induced nausea and vomiting (CINV)] in patients with [MM] undergoing [autologous stem cell transplantation (ASCT)]. CINV is a common and often debilitating side effect of chemotherapy, significantly impacting patient quality of life.
A New Antiemetic Oasis in the Desert of Chemotherapy
The researchers found that [netupitant/palonosetron], given without [dexamethasone], was highly effective in preventing [CINV] in patients with [MM] receiving [high-dose melphalan (HDM)]. The researchers observed [complete response (CR) in 99 (93%) patients at 120 h (overall phase)] and [the percentage of patients with complete control was 93%]. These findings, like a well-stocked oasis providing relief for weary travelers, suggest that [netupitant/palonosetron] could be a valuable new option for preventing CINV in [MM] patients undergoing ASCT.
A More Comfortable Journey Through Chemotherapy
This study offers a glimmer of hope for [MM] patients undergoing [ASCT]. By effectively preventing [CINV], [netupitant/palonosetron] could help patients navigate the challenging journey of chemotherapy with greater comfort and improved quality of life.
Dr.Camel's Conclusion
This study is a significant step forward in the treatment of [MM]. The researchers' findings, like a shimmering oasis in the desert of CINV, highlight the potential of [netupitant/palonosetron] to improve the lives of patients undergoing [ASCT]. This research underscores the importance of developing new and effective treatments to manage the side effects of cancer therapy.
Date :
- Date Completed 2021-12-03
- Date Revised 2021-12-14
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.